Abstract
Gastroenterologists frequently encounter pelvic floor disorders, which affect 10–15% of the population. The anorectum is a complex organ that collaborates with the pelvic floor muscles to preserve fecal continence and enable defecation. A careful clinical assessment is critical for the diagnosis and management of defecatory disorders and fecal incontinence. Newer diagnostic tools (e.g., high resolution manometry and magnetic resonance defecography) provide a refined understanding of anorectal dysfunctions and identify phenotypes in defecatory disorders and fecal incontinence. Conservative approaches including biofeedback therapy are the mainstay for managing these disorders; new minimally-invasive approaches may benefit a subset of patients with fecal incontinence but more controlled studies are needed. This mini-review highlights these advances, current concepts and controversies in the area.
Introduction
Pelvic floor disorders affect 10–15% of the population 1, 2. This mini-review is focused on recent advances in basic science and clinical research in common conditions encountered by practicing gastroenterologists, but is not a comprehensive review of these topics 3, 4.
Advances in Basic Sciences
Anatomy and Physiology of the Anal Sphincters
While the anal sphincters are vital for maintaining continence and defecation 5, our understanding of their neurophysiology lags behind the rest of the enteric nervous system. Recent studies have shed new light on the structure of the internal anal sphincter (IAS), its tone, and innervation. In monkeys, the IAS is thicker than the rectum and organized into “mini-bundles”, which contain nerves and unique stellate-shaped interstitial cells of Cajal 6. Nerves and ICC are not closely associated with one another. These morphological features suggest that intramuscular ICC in the IAS may serve as pacemaker cells rather than as mediators of neuromuscular transmission.
Befitting a sphincter, the IAS has higher resting tone than the rectum. Basal tone in the human IAS is maintained by calcium entry via L-type calcium channels 7–9 and by RhoA-ROCK (RhoA kinase), which enhances myofilament sensitivity to calcium 10. Fascinating data suggest that micro RNAs can modulate the RhoA/ROCK pathway and thereby regulate tone in the rat IAS 11. For example, miRNA 139-5b repressed the RhoA/ROCK pathway and reduced tone while the corresponding anti-miR had the opposite effect. Whether miRNAs alter anal sphincter function in humans is unclear.
Sympathetic nerves provide the primary excitatory input to the anal sphincter in monkeys and humans, but not in mice or rabbits 8. Perhaps these species-dependent differences explain why some species (eg, mouse, rabbits) that defecate more frequently have less sympathetic excitatory innervation than others (ie, monkeys) that defecate less frequently.
Therapeutic options for restoring anal sphincter function in patients with sphincter injury are limited. Surgical repair of sphincter defects restores continence in the short but not long term 12. Recently, bioengineered IAS strips were created by co-culturing human IAS circular smooth muscle strips with mouse fetal enteric neurons, and these appear to retain their integrity and functional characteristics after implantation into mice 13, 14. Translating these advances to patients with damaged sphincters will require isolation and culture of autologous human enteric neuronal progenitor populations to minimize immune reactions and techniques for implantation that do not disrupt other muscles.
Defecatory Disorders
In patients with chronic constipation unresponsive to laxatives, anorectal testing is necessary to identify defecatory disorder(s) (DD) 2, 15. As detailed below, DD may result from disordered function (e.g., rectoanal dyssynergia) or rectal structural disturbances; these may coexist. Defecatory disorders are common in the community with a prevalence of 22 [versus 5.8 for Crohn’s disease] per 100,000 person years 16. While DD have been mostly described in patients without underlying colorectal disease, recent studies also report DD in constipated patients with inflammatory bowel disease, either with native anatomy or ileal pouchitis with anal anastomosis 17, 18.
Clinical Features
Physicians consider certain symptoms (e.g., excessive straining and anal digitation) as suggestive of disordered defecation. However, questionnaire assessments cannot distinguish DD from other causes of chronic constipation 19, 20. Whether an interview, which provides an opportunity to ask follow-on questions, can discriminate between DD and other causes of chronic constipation, is unclear. A recent abstract from Italy suggests that an affirmative response to a different question (i.e., asking patients if they mostly squeezed the anus to defecate) was 82% sensitive and 86% specific for identifying DD 21.
Few physicians meticulously evaluate anal sphincter tone and pelvic floor motion by a digital rectal examination (DRE), even in patients with chronic constipation 22. This is a significant lacuna since a DRE is reasonably accurate relative to manometry for assessing anal resting tone and squeeze function and for identifying dyssynergia 23, 24. Thus, a DRE was 75% sensitive and 87% specific versus dyssynergia documented by manometry 18 but 80% sensitive and 56% specific versus the rectal balloon expulsion test. The lower specificity compared to a rectal balloon expulsion test may perhaps reflect the inability of some people with normal pelvic floor function to simulate the process of defecation during a DRE. Hence, a normal DRE is more useful than an abnormal exam in patients with chronic constipation. Controlled studies evaluating the utility of a DRE alone and integrated with symptoms for identifying DD are necessary.
Pathophysiology
Visual inspection of anorectal manometry tracings suggests that impaired rectal evacuation can be attributed to weak rectal propulsive forces or increased anal outlet resistance (i.e., inadequate relaxation and/or paradoxical contraction of the anal sphincter) 25. A principal components (PC) analysis of anorectal pressures in 295 constipated patients and 62 controls identified these 2 patterns and a third (i.e. hybrid) pattern characterized by low rectal and high anal pressures during evacuation 19 (Figure 1). Since these PCs were, by design, uncorrelated to each other, they reflect distinct underlying pathophysiological mechanisms. The concept that dyssynergia results from “maladaptive learning” of sphincter contraction, perhaps stemming from neglecting the call to defecate in childhood, is plausible. For example, one-third of children with childhood constipation continue to have severe symptoms beyond puberty 26. However, this framework emphasizes “volitional disturbances” but does not integrate visceral dysfunctions (e.g., rectal hyposensitivity 27, increased anal resting pressure [anal hypertension], perineal laxity manifested by excessive perineal descent 28, and delayed colonic transit 29) into the pathophysiology of DD. Some features (e.g., rectal hyposensitivity and delayed transit) improve after successful biofeedback treatment suggesting they are consequences rather than causes of obstructed defecation 30. Studies with high definition manometry confirm that the puborectalis closes the cranial part of the anal canal, thereby preserving fecal continence 36.
Figure 1. Representative examples of anorectal pressure phenotypes identified by high resolution manometry in defecatory disorders.
Pressures at rest, during squeeze and evacuation were recorded by 12 sensors (2 in the rectal balloon and 10 in the anal canal) and are depicted in color; the numbers reflect the distance of sensors from anal verge. High anal, low rectal and hybrid phenotypes are defined by anal, rectal and combined rectoanal dysfunction respectively. During evacuation: (i) anal relaxation was normal in the rectal phenotype but absent in the “high anal” and “hybrid” patterns. Anal resting pressure was also higher in the anal phenotype, (ii) rectal (balloon) pressure increased, as evidenced by color change from blue to green in the rectal balloon, in the high anal phenotype only.
Rectal distention induces involuntary relaxation of the IAS. At a higher volume, rectal distention is perceived and subsequently evokes contraction of the external sphincter. Likewise, distention induces a sensori-motor response, which manometrically, seems to result from puborectalis contraction, and coincides with the desire to defecate 31. These observations are reminiscent of prior studies which suggest that the desire to defecate is mediated not by rectal distention but by the rectal contractile response to distention 32. Further studies are necessary to ascertain if sensori-motor response is a cause or consequence of the desire to defecate.
Diagnostic Testing
Anorectal manometry and a rectal balloon expulsion test, followed by barium or MR defecography if necessary are recommended in constipated patients when diet and lifestyle modification and empiric laxative therapy have failed 2, 15 (Table 1). Clinicians can probably diagnose DD with reasonable confidence in patients who have typical symptoms, a confirmatory DRE, and an abnormal balloon expulsion test.
Table 1.
Summary of Anorectal Tests
Anorectal Parameter (Method) | Methodological Issues | Clinical Utility |
---|---|---|
|
|
|
Anal sphincter structure (Ultrasound or MRI) |
|
|
Puborectalis structure and function (Manometry and MRI) |
|
|
Rectal evacuation (Rectal balloon expulsion and proctography with fluoroscopy or MRI) |
|
|
Anorectal and pelvic floor motion (Proctography with fluoroscopy or MRI) |
|
|
Anal sphincter innervation (Needle or surface EMG) |
|
|
Rectal compliance and sensation (Manual or barostat-driven distention of a rectal balloon) |
|
|
Until the advent of high resolution manometry catheters 5 years ago, anal manometry was performed with water-perfused or solid-state sensors. High resolution catheters provide a single pressure, averaged around the circumference, at 6-mm intervals, and straddle the entire length of the anal canal, obviating the need for a station pull-through maneuver 33. High definition catheters use 256 circumferentially distributed pressure sensors that provide greater definition of sphincter morphology and defects 34. Because they have more sensors, these new systems provide better resolution relative to traditional (water-perfused or solid-state) systems. However, only the highest pressure recorded by the catheter at any instant is used to calculate average or maximum resting or squeeze pressure, which is why normal values are higher than for traditional systems 33. Data from all sensors is used to assess sphincter symmetry by high definition manometry.
Recent studies have highlighted two challenges with diagnosing DD. First, based on physical principles, the rectoanal gradient (i.e., ratio of or difference between rectal and anal pressure) during evacuation should normally be positive in people without dyssynergia 33. Consistent with these principles, this gradient is low in dyssynergia and increases after biofeedback therapy 35, reflecting improved rectoanal coordination. However, there is considerable overlap in this gradient between asymptomatic subjects, patients with dyssynergia and chronic pelvic pain without constipation 35, 36. Indeed, with high resolution manometry, this gradient was negative [i.e., anal > rectal pressure] in a majority of asymptomatic women 19,33. Perhaps these findings are partly explained by the challenge of replicating the process of defecation in the left lateral position with an empty rectum. Coaching patients while they perform maneuvers might be useful; in one study coaching changed the diagnosis based on manometry from ‘pathologic’ to ‘normal’ values in 14/31 patients with incontinence and 12/39 with DD 37.
Second, there is limited agreement among tests used to diagnose DD and there is no single criterion standard for diagnosing dyssynergia. For example, 51% of 125 patients with chronic constipation had dyssynergia by defecography 38; of those, only approximately 50% had an abnormal balloon expulsion test and only 50% had abnormal pelvic floor relaxation by surface electromyography. A meta-analysis of 79 studies with 7591 patients who had chronic constipation reported that the prevalence of findings suggestive of abnormal defecation ranged from 14.9% (95% CI 7.9–26.3) for absent opening of the anorectal angle on defecography to 47.7% (95% CI 39.5–56.1) for a dyssynergic pattern with manometry, and 52.9% (95% CI 44.3–61.3) for a dyssynergic pattern by ultrasound 39. Taken together, these observations do not undermine the entity of dyssynergia but rather emphasize the phenotypic heterogeneity of DD 28, underscore the influence of the nature of rectal contents as also the sensation evoked by rectal distention on defecation 40, and suggest there is considerable scope for refining anorectal tests for diagnosing DD. Currently, high resolution manometry is primarily helpful to stratify patients into subpopulations, and is not more useful than standard anorectal manometric techniques for managing DD.
Management
Dyssynergic defecation should be managed by biofeedback therapy 41. Successful protocols have typically employed 5–6 training sessions lasting 30–60 minutes each and spaced two weeks apart. The goals of therapy are to: (1) educate patients about disordered defecation; (2) coordinate increased intra-abdominal pressure with pelvic floor muscle relaxation during evacuation; and (3) practice simulated defecation with a balloon, aided by a therapist. Some centers also provide sensory retraining for restoring the sensation of rectal filling.
While these studies demonstrate the efficacy of biofeedback therapy in tertiary centers, more studies regarding its effectiveness in clinical practice are necessary. The skill and experience of the therapist are critical factors influencing the response to biofeedback therapy; this expertise is not widely available. In a randomized controlled trial, home biofeedback therapy was equally effective and cheaper than office based biofeedback therapy 42. The anorectal factors that predict the response to biofeedback therapy, the ingredients of biofeedback therapy which are critical for its success, and the mechanism(s) by which biofeedback therapy improves symptoms and pathophysiology in dyssynergia are unclear. The latency of cortical evoked potentials in response to rectal or anal stimulation is prolonged and declines after biofeedback therapy in patients with dyssynergic defecation, suggesting improved corticoanal function 43. Biofeedback therapy was also effective in approximately 60% of patients with inflammatory bowel disease and DD17, 18.
Other therapeutic approaches
While sacral nerve stimulation (SNS) has been used to treat chronic constipation, the data are mostly uncontrolled, and the response to treatment is inconsistent 44. Two uncontrolled studies including 24 patients with DD reported improved outcomes after SNS for constipation 45, 46. The mechanisms by which SNS might improve symptoms in DD are unclear. A small study in patients with DD and rectal hyposensitivity reported that rectal sensory thresholds were lower when SNS was on than off, suggesting improved sensation 46. SNS may also modulate colonic motility; suprasensory but not subsensory stimulation increased colonic propagating sequences 47. Long term, controlled trials with assessment of subjective and objective features are necessary to clarify the role of SNS in DD, particularly in patients who have failed biofeedback therapy.
The recent AGA Technical Review on Constipation concluded there was insufficient evidence to recommend the stapled transanal resection procedure or injection of botulinum toxin into the pelvic floor muscles for managing chronic constipation 2. Likewise, a randomized controlled trial observed that botulinum toxin was not useful for levator ani syndrome; biofeedback therapy is effective for this disorder 36, 48.
Fecal Incontinence
Fecal incontinence (FI) refers to the recurrent uncontrolled passage of feces not related to a temporary diarrheal illness (eg, acute gastroenteritis). In non-institutionalized adults, the prevalence is 2.2% to 15.3%. FI substantially impairs quality of life 1, 49, 50. Risk factors include age, diarrhea, urgency to defecate, obstetric injury and a variety of medical conditions 23–26.
Etiology and Pathophysiology
Initial studies with endoanal ultrasound uncovered a high prevalence (i.e., up to 30%) of obstetric anal sphincter injury in women with FI, prompting the concept that obstetric trauma is an important risk factor in women 51. After external anal sphincter myotomy in a rabbit model, there was progressive fibrosis, impaired muscle length-tension relationships, and disorganized muscle fiber distribution, which persisted up to 12 weeks after injury 52. These findings suggest that healing after sphincter injury may not improve function.
On average, FI begins in the 5–7th decade 21,50, which suggests that factors in addition to obstetric anal injury play a role in FI. Indeed, data from community-based studies demonstrate that diarrhea, and other conditions (e.g., cholecystectomy, smoking, and increased BMI) rather than a complicated obstetric history (e.g., forceps use) are risk factors in community women with late-onset FI 53–56. Of interest, the risk of FI in current smokers is comparable to patients with irritable bowel syndrome or a cholecystectomy 55. Moreover, smoking was the only risk factor for external sphincter atrophy by MRI 56.
Nerve injury also contributes to FI. Pudendal nerve terminal motor latencies are not recommended for identifying pudendal nerve injury 57. Hence, needle electromyography is the only established technique for identifying anal neurogenic injury. A recent controlled study observed neurogenic or muscle injury in 55% of a selected cohort of 20 women with FI, which is comparable to that reported previously 58. Moreover, even in asymptomatic nulliparous women, increased age was associated with neurogenic injury, which partly explained weak squeeze pressures.
Using techniques that are widely used to assess somatic pathways, evoked potentials elicited by peripheral or central, electrical or magnetic stimulation can be used to assess the neural pathways mediating anorectal functions. Depending on the site of stimulation and recording, afferent and efferent pathways can be evaluated 59, 60. Confirming proof of concept, motor evoked potentials after anal and rectal stimulation were prolonged in patients with spinal cord injury and bowel dysfunction 61 and also in FI 62. These techniques may enhance our understanding of anorectal dysfunctions, in particular the mechanisms of impaired voluntary relaxation in DD or unexplained anal weakness in FI. However, further validation is necessary. For example, the precise cortical target of transcranial magnetic stimulation is unclear 63. Spinal magnetic stimulation usually activates spinal nerves at the neuroforamina but not in the spinal canal, i.e., the cauda equina 64. With supramaximal stimulation, which is now possible with a novel coil, the magnetic augmented translumbosacral stimulation coil, the most proximal part of the cauda equina can also be reliably activated. Hence, it should be possible to measure the cauda equina and cortico-conus motor-conduction times.
In addition to anal weakness, rectal distention by a barostat demonstrates increased rectal stiffness and reduced rectal capacity, which is associated with the symptom of rectal urgency and with increased rectal sensitivity, in a subset of women with FI 65 (Table 1). A barostat measures rectal volumes and pressures but not diameter. Rectal diameter, hence rectal stress-strain relationships (or stiffness) can be directly measured by integrating MRI with rectal balloon distention. These studies confirmed increased rectal stiffness in FI 66.
Diagnostic Testing
Endoscopy, and when microscopic colitis is considered with colonic biopsies, should be considered 67. A rigorous trial of conservative measures is justified before diagnostic testing, particularly in older patients, those with mild symptoms, and bowel disturbances 67. Anorectal manometry, rectal sensation, and rectal balloon expulsion are useful initial tests. In selected patients with reduced anal pressures, anal imaging and/or anal sphincter EMG are useful (Table 1).
Management
Conservative therapy
Three key studies highlight the role of conservative therapy and placebo responses in FI. Norton et al observed that symptoms improved in approximately 54% of patients with FI who were instructed in diet, fluids, techniques to improve evacuation, a bowel training program, titration of antidiarrheal medication if necessary, and practical management in nine 40–60-minute sessions over 3–6 months by a specialist nurse 68. In another RCT of 108 patients, 22% of patients responded to conservative therapy for 4 weeks 69. Among non-responders to conservative therapy, EMG-assisted biofeedback was superior to pelvic floor exercises alone. More recently, a > 50% reduction in the number of days and episodes of FI was reported by 36% and 32% respectively of women with FI treated with placebo alone for 4 weeks 70. However, these conservative therapies were administered by specialized therapists and not busy practicing physicians. Nonetheless, conservative therapies will benefit approximately 25% of patients and should be tried first. These conservative measures include reduced intake of foods (e.g., poorly absorbed carbohydrates such as fructose, sorbitol, and others, caffeine) that can cause or aggravate diarrhea and/or rectal urgency, urge suppression techniques, and anti-diarrheal agents [e.g., loperamide].
Clonidine increases rectal compliance and reduces rectal sensation and improves symptoms in patients with diarrhea-predominant IBS 71, 72. In an uncontrolled study, clonidine improved continence 73. In a controlled study, clonidine reduced diarrhea and tended to reduce the number of days with FI, but overall effects were not significant 70.
Biofeedback Therapy
For those failing medical therapy, biofeedback therapy designed to improve anal sphincter and puborectalis tone, strength and endurance, and anorectal coordination remains the mainstay. Randomized controlled trials demonstrate that biofeedback therapy is superior to Kegel exercises 69. A small study did not identify significant differences between sustained squeeze maneuvers, which is the standard approach, and a combination of rapid and sustained squeeze maneuvers 74.
Minimally-invasive/surgical options
With the widespread recognition that success rates decline with time after the procedure, anal sphincteroplasty is primarily reserved for women with postpartum FI; for example, only 21% were continent at 40 months in one study 12. Sacral nerve stimulation (SNS) and anal submucosal injection of a “bulking agent” (dextranomer in stabilized hyaluronic acid [NASHA Dx]) are now FDA-approved for the treatment of FI.
For both studies, success was defined by a ≥ 50% reduction in the number of incontinent episodes per week. SNS is a staged procedure, i.e., when symptoms respond to temporary stimulation for 3 weeks, the device is implanted subcutaneously (i.e., “permanent stimulation). In the pivotal US multicenter trial, 90% of 120 patients proceeded from temporary to permanent stimulation 75. Five-year follow up was available in 76 of 120 (63%) patients; 36% reported complete continence and 89% were deemed a therapeutic success 76.
However, most studies with SNS were uncontrolled. In one cross-over study of 34 patients, the number of episodes of FI declined by 90% during stimulation versus 76% without stimulation 77. The discrepancy between symptom-improvement and relatively minor effects on anorectal functions is puzzling 78. Recent data suggest that SNS but not sham stimulation increased the frequency of retrograde propagated sequences throughout the colon. Similar to anti-diarrheal agents, these effects may be anticipated to delay colonic transit 78. In contrast SNS increased colonic propagating sequences in constipation 47. Perhaps differences in baseline colonic motor activity partly explain why SNS may have different effects on colonic motility in constipation and FI but this needs more work.
In the pivotal trial with 206 patients, the 6 month response as defined above was higher for NASHA Dx (52%) than sham injections (31%) 79, yielding a NNT of 4.4. Eighty percent of patients in the active treatment group required a second injection 1 month after the initial procedure. With 2 exceptions (i.e., rectal abscess, prostatic abscess), most adverse events were minor. Treatment did not significantly improve FI quality of life; data for complete continence and effects on anorectal physiology or imaging were not provided 80, 81. Another controlled trial with 126 patients reported significant improvement in FI symptom severity and QOL in patients who were randomized to pelvic floor biofeedback therapy and separately to NASHA Dx 82; the efficacy of these approaches was not different. Biofeedback therapy increased anal squeeze pressure but NASHA Dx did not increase anal resting or squeeze pressre. Hence, the magnitude of benefit, mechanisms of action, long term effects, and factors that predict response to therapy merit further study.
Summary
Significant advances in basic science studies and development of newer diagnostic techniques in humans have advanced our understanding of the multifaceted dysfunctions that contribute to pelvic floor disorders.
Defecatory disorders are a common cause of chronic constipation. While symptoms and a careful digital rectal examination are very useful for identifying defecatory disorders, anorectal tests are necessary to confirm the diagnosis. In most patients, anorectal manometry and a rectal balloon expulsion test suffice. In some patients, defecography, either with barium or MRI are necessary to confirm or exclude the diagnosis. Pelvic floor retraining by biofeedback therapy represents the mainstay for managing defecatory disorders.
Fecal incontinence is a common and often distressing symptom. Bowel dysfunctions and anorectal sensorimotor dysfunctions are the key pathophysiological mechanisms. Management relies upon conservative measures, pelvic floor retraining by biofeedback therapy in patients who do not respond to conservative measures, and sacral nerve simulation or other surgical approaches for patients who are refractory to medical therapy.
In DD, the scientific and clinical priorities are to refine diagnostic tests, our understanding of phenotypes in these disorders, and the impact of these phenotypes on therapy. Moreover, there is an urgent need to increase access and coverage for pelvic floor retraining by biofeedback therapy and to develop alternative approaches for these disorders. In FI, the emphasis is on identifying the symptom and the likely cause, followed by targeted therapy. Future studies should also apply advances from basic science to humans, refine our understanding of phenotypes in these disorders, and develop new approaches for managing these disorders based on our understanding of the underlying mechanisms, and to compare the efficacy of various therapeutic approaches in rigorously controlled clinical trials.
Figure 2.
Algorithm for managing defecatory disorders Reproduced with permission from Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association Medical Position Statement on Constipation Gastroenterologygy 2013; 144(1):211–17 (left panel)
Figure 3.
Algorithm for managing fecal incontinence.
Acknowledgments
This study was supported in part by USPHS NIH Grants R01 DK78924 and by R01DK 57100-07
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- 1.Bharucha AE, Zinsmeister AR, Locke GR, Seide B, McKeon K, Schleck CD, Melton LJI. Prevalence and burden of fecal incontinence: A population based study in women. Gastroenterology. 2005;129:42–49. doi: 10.1053/j.gastro.2005.04.006. [DOI] [PubMed] [Google Scholar]
- 2.Bharucha AE, Locke GR, Pemberton JH. AGA Practice Guideline on Constipation: Technical Review. Gastroenterology. 2013;144:218–238. doi: 10.1053/j.gastro.2012.10.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Rao SSC. Advances in diagnostic assessment of fecal incontinence and dyssynergic defecation. Clinical Gastroenterology & Hepatology. 2010;8:910–9. doi: 10.1016/j.cgh.2010.06.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Whitehead WE, Bharucha AE. Diagnosis and treatment of pelvic floor disorders: what’s new and what to do. Gastroenterology. 2010;138:1231–5. doi: 10.1053/j.gastro.2010.02.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bharucha AE. Pelvic floor: anatomy and function. Neurogastroenterology & Motility. 2006;18:507–19. doi: 10.1111/j.1365-2982.2006.00803.x. [DOI] [PubMed] [Google Scholar]
- 6.Cobine CA, Hennig GW, Bayguinov YR, Hatton WJ, Ward SM, Keef KD. Interstitial cells of Cajal in the cynomolgus monkey rectoanal region and their relationship to sympathetic and nitrergic nerves. American Journal of Physiology - Gastrointestinal & Liver Physiology. 2010;298:G643–56. doi: 10.1152/ajpgi.00260.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Cook TA, Brading AF, Mortensen NJ. Effects of nifedipine on anorectal smooth muscle in vitro. Diseases of the Colon & Rectum. 1999;42:782–7. doi: 10.1007/BF02236936. [DOI] [PubMed] [Google Scholar]
- 8.Cobine CA, Fong M, Hamilton R, Keef KD. Species dependent differences in the actions of sympathetic nerves and noradrenaline in the internal anal sphincter. Neurogastroenterology & Motility. 2007;19:937–45. doi: 10.1111/j.1365-2982.2007.00982.x. [DOI] [PubMed] [Google Scholar]
- 9.Bharucha AE, Edge J, Zinsmeister AR. Effect of nifedipine on anorectal sensorimotor functions in health and fecal incontinence. American Journal of Physiology - Gastrointestinal & Liver Physiology. 2011;301:G175–80. doi: 10.1152/ajpgi.00557.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Rattan S, Singh J. RhoA/ROCK pathway is the major molecular determinant of basal tone in intact human internal anal sphincter. American Journal of Physiology - Gastrointestinal & Liver Physiology. 2012;302:G664–75. doi: 10.1152/ajpgi.00430.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Singh J, Addya S, Fortina P, Rattan SC. Sa2030 Role of MicroRNA-139-5p (Mir-139-5p) in the Myogenic Basal Tone of Internal Anal Sphincter (IAS) vs. the Phasic Rectal Smooth Muscle (RSM): Studies in Purified Smooth Muscle Cells (SMCS) Gastroenterology. 2013;144:S–364. [Google Scholar]
- 12.Wald A. Clinical practice. Fecal incontinence in adults New England Journal of Medicine. 2007;356:1648–55. doi: 10.1056/NEJMcp067041. [DOI] [PubMed] [Google Scholar]
- 13.Raghavan S, Gilmont RR, Miyasaka EA, Somara S, Srinivasan S, Teitelbaum DH, Bitar KN. Successful implantation of bioengineered, intrinsically innervated, human internal anal sphincter. Gastroenterology. 2011;141:310–9. doi: 10.1053/j.gastro.2011.03.056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Bitar KN, Raghavan S. Intestinal tissue engineering: current concepts and future vision of regenerative medicine in the gut. Neurogastroenterology & Motility. 2012;24:7–19. doi: 10.1111/j.1365-2982.2011.01843.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Bharucha AE, Dorn SD, Lembo A, Pressman A American Gastroenterological A. American gastroenterological association medical position statement on constipation. Gastroenterology. 2013;144:211–7. doi: 10.1053/j.gastro.2012.10.029. [DOI] [PubMed] [Google Scholar]
- 16.Noelting N, Eaton J, Thapa P, Zinsmeister AR, Locke GR, Bharucha AE. Incidence Rate and Characteristics of Clinically Diagnosed Defecatory Disorders in the Community. Gastroenterology. 2013 doi: 10.1111/nmo.12868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Perera LP, Ananthakrishnan AN, Zadvornova Y, Issa M, Naik AS, Skaros S, Johnson K, Tyler K, Ward A, Massey BT. T1355 High Prevalence of Obstructive Defecation in Inflammatory Bowel Disease Patients in Remission. Gastroenterology. 2010;138:S–544. [Google Scholar]
- 18.Tremaine WJ, Raffals LH, Bharucha AE, Timmons LJ, Pemberton JH, Camilleri M. 561 Inflammatory Bowel Disease and Non-Relaxing Pelvic Floor Dysfunction. Gastroenterology. 2013;144:S–104. [Google Scholar]
- 19.Ratuapli S, Bharucha AE, Noelting J, Harvey D, Zinsmeister AR. Phenotypic Identification and Classification of Functional Defecatory Disorders Using High Resolution Anorectal Manometry. Gastroenterology. 2013;144:314–322. doi: 10.1053/j.gastro.2012.10.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Rai J, Chey WD, Maneerattanaporn M, Baker J, Saad RJ. Tu2013 Do Constipation Symptoms Identify Patients With Dyssynergic Defecation? Gastroenterology. 2012;142:S–901. [Google Scholar]
- 21.Chiarioni G, Kim SM, Whitehead WE. Sa2038 Dyssynergic Defecation Can Be Diagnosed by Questionnaire and Physical Examination. Gastroenterology. 2013;144:S–366. [Google Scholar]
- 22.Wong RK, Drossman DA, Bharucha AE, Rao SS, Wald A, Morris CB, Oxentenko AS, Ravi K, Van Handel DM, Edwards H, Hu Y, Bangdiwala S. The digital rectal examination: a multicenter survey of physicians’ and students’ perceptions and practice patterns. American Journal of Gastroenterology. 2012;107:1157–63. doi: 10.1038/ajg.2012.23. [DOI] [PubMed] [Google Scholar]
- 23.Orkin BA, Sinykin SB, Lloyd PC. The digital rectal examination scoring system (DRESS) Diseases of the Colon & Rectum. 2010;53:1656–60. doi: 10.1007/DCR.0b013e3181f23c85. [DOI] [PubMed] [Google Scholar]
- 24.Tantiphlachiva K, Rao P, Attaluri A, Rao SSC. Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clinical Gastroenterology & Hepatology. 2010;8:955–60. doi: 10.1016/j.cgh.2010.06.031. [DOI] [PubMed] [Google Scholar]
- 25.Rao SS, Mudipalli RS, Stessman M, Zimmerman B. Investigation of the utility of colorectal function tests and Rome II criteria in dyssynergic defecation (Anismus) Neurogastroenterology & Motility. 2004;16:589–96. doi: 10.1111/j.1365-2982.2004.00526.x. [DOI] [PubMed] [Google Scholar]
- 26.van Ginkel R, Reitsma JB, Buller HA, van Wijk MP, Taminiau JAJM, Benninga MA. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology. 2003;125:357–63. doi: 10.1016/s0016-5085(03)00888-6. [DOI] [PubMed] [Google Scholar]
- 27.Gladman MA, Lunniss PJ, Scott SM, Swash M. Rectal hyposensitivity. American Journal of Gastroenterology. 2006;101:1140–51. doi: 10.1111/j.1572-0241.2006.00604.x. [DOI] [PubMed] [Google Scholar]
- 28.Bharucha AE, Fletcher JG, Seide B, Riederer SJ, Zinsmeister AR. Phenotypic Variation in Functional Disorders of Defecation. Gastroenterology. 2005;128:1199–1210. doi: 10.1053/j.gastro.2005.03.021. [DOI] [PubMed] [Google Scholar]
- 29.Ravi K, Bharucha AE, Camilleri M, Rhoten D, Bakken T, Zinsmeister AR. Phenotypic Variation Of Colonic Motor Functions In Chronic Constipation. Gastroenterology. 2009;138:89–97. doi: 10.1053/j.gastro.2009.07.057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology. 2005;129:86–97. doi: 10.1053/j.gastro.2005.05.015. [DOI] [PubMed] [Google Scholar]
- 31.Cheeney G, Remes-Troche JM, Attaluri A, Rao SSC. Investigation of anal motor characteristics of the sensorimotor response (SMR) using 3-D anorectal pressure topography. American Journal of Physiology - Gastrointestinal & Liver Physiology. 2011;300:G236–40. doi: 10.1152/ajpgi.00348.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Corsetti M, Cesana B, Bhoori S, Basilisco G. Rectal Hypersensitivity to Distention in Patients with Irritable Bowel Syndrome: Role of Distention Rate. Clinical Gastroenterology and Hepatology. 2004;2:49–56. doi: 10.1016/s1542-3565(03)00291-x. [DOI] [PubMed] [Google Scholar]
- 33.Noelting J, Ratuapli SK, Bharucha AE, Harvey D, Ravi K, Zinsmeister AR. Normal Values For High-Resolution Anorectal Manometry In Healthy Women: Effects Of Age And Significance Of Rectoanal Gradient. American Journal of Gastroenterology. 2012;107:1530–6. doi: 10.1038/ajg.2012.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Nguyen M, Cheeney G, Tantiphlachiva K, Valestin J, Attaluri A, Rao SS. 169 Investigation of High-Definition Anorectal Pressure Topography (HDM) in Patients With Constipation and Fecal Incontinence. Gastroenterology. 2010;138:S-30–S-31. [Google Scholar]
- 35.Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. American Journal of Gastroenterology. 1998;93:1042–50. doi: 10.1111/j.1572-0241.1998.00326.x. [DOI] [PubMed] [Google Scholar]
- 36.Chiarioni G, Nardo A, Vantini I, Romito A, Whitehead W. Biofeedback is superior to electrogalvanic stimulation and massage for treatment of levator ani syndrome. Gastroenterology. 2010;138:1321–9. doi: 10.1053/j.gastro.2009.12.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Heinrich H, Fruehauf H, Sauter M, Steingotter A, Fried M, Schwizer W, Fox M. The effect of standard compared to enhanced instruction and verbal feedback on anorectal manometry measurements. Neurogastroenterol Motil. 2013;25:e163. doi: 10.1111/nmo.12038. [DOI] [PubMed] [Google Scholar]
- 38.Bordeianou L, Savitt L, Dursun A. Measurements of pelvic floor dyssynergia: which test result matters? Diseases of the Colon & Rectum. 2011;54:60–5. doi: 10.1007/DCR.0b013e3181fd2373. [DOI] [PubMed] [Google Scholar]
- 39.Videlock EJ, Lembo A, Cremonini F. Diagnostic testing for dyssynergic defecation in chronic constipation: meta-analysis. Neurogastroenterology & Motility. 2013;25:509–20. doi: 10.1111/nmo.12096. [DOI] [PubMed] [Google Scholar]
- 40.Rao SSC, Kavlock R, Rao S. Influence of body position and stool characteristics on defecation in humans. American Journal of Gastroenterology. 2006;101:2790–2796. doi: 10.1111/j.1572-0241.2006.00827.x. [DOI] [PubMed] [Google Scholar]
- 41.Rao SSC, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, Zimmerman B, Schulze K. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clinical Gastroenterology & Hepatology. 2007;5:331–8. doi: 10.1016/j.cgh.2006.12.023. [DOI] [PubMed] [Google Scholar]
- 42.Rao SS, Valestin J, Brown CK, Hamdy S, Bradley C, Schulze KS, Zimmerman B. Home or Office Biofeedback Therapy for Dyssynergic Defecation – Randomized Controlled Trial. Gastroenterology. 2011;140:S–160. [Google Scholar]
- 43.Rao SS, Tantiphlachiva K, Remes-Troche J, Attaluri A, Valestin J, Cheeney G, Hamdy S. Does Biofeedback Therapy Modulate Anorectal (Gut)-Brain Axis in Patients With Dyssynergic Defecation? Gastroenterology. 2011;140:S–367. [Google Scholar]
- 44.Thomas GP, Dudding TC, Rahbour G, Nicholls RJ, Vaizey CJ. Sacral nerve stimulation for constipation. British Journal of Surgery. 2013;100:174–81. doi: 10.1002/bjs.8944. [DOI] [PubMed] [Google Scholar]
- 45.Holzer B, Rosen HR, Novi G, Ausch C, Holbling N, Hofmann M, Schiessel R. Sacral nerve stimulation in patients with severe constipation [see comment] Diseases of the Colon & Rectum. 2008;51:524–29. doi: 10.1007/s10350-007-9160-9. discussion 529–30. [DOI] [PubMed] [Google Scholar]
- 46.Knowles CH, Thin N, Gill K, Bhan C, Grimmer K, Lunniss PJ, Williams NS, Scott SM. Prospective randomized double-blind study of temporary sacral nerve stimulation in patients with rectal evacuatory dysfunction and rectal hyposensitivity. Annals of Surgery. 2012;255:643–9. doi: 10.1097/SLA.0b013e318247d49f. [DOI] [PubMed] [Google Scholar]
- 47.Dinning PG, Hunt LM, Arkwright JW, Patton V, Szczesniak MM, Wiklendt L, Davidson JB, Lubowski DZ, Cook IJ. Pancolonic motor response to subsensory and suprasensory sacral nerve stimulation in patients with slow-transit constipation. The British journal of surgery. 2012;99:1002–10. doi: 10.1002/bjs.8760. [DOI] [PubMed] [Google Scholar]
- 48.Rao SSC, Paulson J, Mata M, Zimmerman B. Clinical trial: effects of botulinum toxin on Levator ani syndrome--a double-blind, placebo-controlled study. Alimentary Pharmacology and Therapeutics. 2009;29:985–91. doi: 10.1111/j.1365-2036.2009.03964.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Bharucha AE, Zinsmeister AR, Locke GR, Schleck C, McKeon K, Melton LJ. Symptoms and quality of life in community women with fecal incontinence. Clinical Gastroenterology & Hepatology. 2006;4:1004–9. doi: 10.1016/j.cgh.2006.01.003. [DOI] [PubMed] [Google Scholar]
- 50.Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, Weidner A, Weinstein M, Ye W, Network PFD. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137:512–7. doi: 10.1053/j.gastro.2009.04.054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Sultan AH, Kamm MA, Hudson CN, Thomas JM, Bartram CI. Anal-sphincter disruption during vaginal delivery. New England Journal of Medicine. 1993;329:1905–11. doi: 10.1056/NEJM199312233292601. [DOI] [PubMed] [Google Scholar]
- 52.Rajasekaran MR, Seo Y, Salehi M, Bhargava V, Sinha S, Mittal RK. 465 Myoarchitectural and Functional Alteration in the External Anal Sphincter Muscle Following Experimental Surgical Myotomy. Gastroenterology. 2013;144:S–83. doi: 10.1152/ajpgi.00450.2013. [DOI] [PubMed] [Google Scholar]
- 53.Bharucha AE, Zinsmeister AR, Locke GR, Seide B, McKeon K, Schleck CD, Melton LJI. Risk Factors for Fecal Incontinence: A Population Based Study in Women. American Journal of Gastroenterology. 2006;101:1305–12. doi: 10.1111/j.1572-0241.2006.00553.x. [DOI] [PubMed] [Google Scholar]
- 54.Bharucha AE, Seide B, Zinsmeister AR, Melton JL. Relation of bowel habits to fecal incontinence in women. American Journal of Gastroenterology. 2008;103:1470–5. doi: 10.1111/j.1572-0241.2008.01792.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Bharucha AE, Zinsmeister AR, Schleck CD, Melton LJ., 3rd Bowel disturbances are the most important risk factors for late onset fecal incontinence: a population-based case-control study in women. Gastroenterology. 2010;139:1559–66. doi: 10.1053/j.gastro.2010.07.056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Bharucha AE, Fletcher JG, Melton LJ, 3rd, Zinsmeister AR. Obstetric Trauma, Pelvic Floor Injury And Fecal Incontinence: A Population-Based Case-Control Study. American Journal of Gastroenterology. 2012;107:902–11. doi: 10.1038/ajg.2012.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Diamant NE, Kamm MA, Wald A, Whitehead WE. American Gastroenterological Association Medical Position Statement on Anorectal Testing Techniques. Gastroenterology. 1999;116:732–760. doi: 10.1016/s0016-5085(99)70194-0. [DOI] [PubMed] [Google Scholar]
- 58.Bharucha AE, Daube J, Litchy W, Traue J, Edge J, Enck P, Zinsmeister AR. Anal sphincteric neurogenic injury in asymptomatic nulliparous women and fecal incontinence. American Journal of Physiology - Gastrointestinal & Liver Physiology. 2012;303:G256–62. doi: 10.1152/ajpgi.00099.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Harris ML, Hobson AR, Hamdy S, Thompson DG, Akkermans LM, Aziz Q. Neurophysiological evaluation of healthy human anorectal sensation. American Journal of Physiology - Gastrointestinal & Liver Physiology. 2006;291:G950–8. doi: 10.1152/ajpgi.00010.2006. [DOI] [PubMed] [Google Scholar]
- 60.Remes-Troche JM, Tantiphlachiva K, Attaluri A, Valestin J, Yamada T, Hamdy S, Rao SSC. A bi-directional assessment of the human brain-anorectal axis. Neurogastroenterology & Motility. 2011;23:240–8. e117–8. doi: 10.1111/j.1365-2982.2010.01619.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Tantiphlachiva K, Attaluri A, Valestin J, Yamada T, Rao SSC. Translumbar and transsacral motor-evoked potentials: a novel test for spino-anorectal neuropathy in spinal cord injury. American Journal of Gastroenterology. 2011;106:907–14. doi: 10.1038/ajg.2010.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Rao SS, Tantiphlachiva K, Attaluri A, Paulson JA, Remes-Troche JM, Yamada T. S1826 Translumbar and Transsacral Magnetic Stimulation–a Novel Test of Assessing Anorectal Neuropathy in Fecal Incontinence. Gastroenterology. 2008;134:A–278. [Google Scholar]
- 63.Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Mazzone P, Insola A, Tonali PA, Rothwell JC. The physiological basis of transcranial motor cortex stimulation in conscious humans. Clinical Neurophysiology. 2004;115:255–66. doi: 10.1016/j.clinph.2003.10.009. [DOI] [PubMed] [Google Scholar]
- 64.Matsumoto H, Hanajima R, Terao Y, Ugawa Y. Magnetic-motor-root stimulation: review. Clinical Neurophysiology. 2013;124:1055–67. doi: 10.1016/j.clinph.2012.12.049. [DOI] [PubMed] [Google Scholar]
- 65.Bharucha AE, Fletcher JG, Harper CM, Hough D, Daube JR, Stevens C, Seide B, Riederer SJ, Zinsmeister AR. Relationship between symptoms and disordered continence mechanisms in women with idiopathic fecal incontinence. Gut. 2005;54:546–55. doi: 10.1136/gut.2004.047696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Bharucha AE, Holmes D, Haider C, Carrascal CA, Edge J, Manduca A, Zinsmeister AR. Increased Rectal Stiffness in Women With Urge-Predominant Fecal Incontinence. Gastroenterology. 2013;144:S–82. [Google Scholar]
- 67.Bharucha AE, Wald AM. Anorectal disorders. American Journal of Gastroenterology. 2010;105:786–94. doi: 10.1038/ajg.2010.70. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm MA. Randomized Controlled Trial of Biofeedback for Fecal Incontinence. Gastroenterology. 2003;125:1320–1329. doi: 10.1016/j.gastro.2003.09.039. [DOI] [PubMed] [Google Scholar]
- 69.Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman DA, Whitehead W. Randomized controlled trial shows biofeedback to be superior to alternative treatments for fecal incontinence. Diseases of the Colon & Rectum. 2009;52:1730–1737. doi: 10.1007/DCR.0b013e3181b55455. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Bharucha AE, Fletcher JG, Camilleri M, Edge J, Carlson P, Zinsmeister AR. A Placebo-Controlled Study of Clonidine on Symptoms in Women With Fecal Incontinence. Clinical Gastroenterology and Hepatology. 2013 doi: 10.1016/j.cgh.2013.06.035. In press. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Malcolm A, Camilleri M, Kellow J. Clonidine alters rectal motor and sensory function in irritable bowel syndrome. Gastroenterology. 1999;116:A1035. [Google Scholar]
- 72.Camilleri M, Kim D-Y, McKinzie S, Kim H-J, Thomforde G, Burton D, Low PA, Zinsmeister AR. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clinical Gastroenterology & Hepatology. 2003;1:111–121. doi: 10.1053/cgh.2003.50019. [DOI] [PubMed] [Google Scholar]
- 73.Bharucha AE, Seide BM, Zinsmeister AR. The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence. Alimentary Pharmacology & Therapeutics. 2010;32:681–688. doi: 10.1111/j.1365-2036.2010.04391.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Bartlett L, Sloots K, Nowak M, Ho Y-H. Biofeedback for fecal incontinence: a randomized study comparing exercise regimens. Diseases of the Colon & Rectum. 2011;54:846–56. doi: 10.1007/DCR.0b013e3182148fef. [DOI] [PubMed] [Google Scholar]
- 75.Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, Chan M, Ayscue JM, Shobeiri AS, Margolin D, England M, Kaufman H, Snape WJ, Mutlu E, Chua H, Pettit P, Nagle D, Madoff RD, Lerew DR, Mellgren A. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Annals of Surgery. 2010;251:441–9. doi: 10.1097/SLA.0b013e3181cf8ed0. [DOI] [PubMed] [Google Scholar]
- 76.Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, Madoff RD, Stromberg K, Coller JA, Group SNSS. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Diseases of the Colon & Rectum. 2013;56:234–45. doi: 10.1097/DCR.0b013e318276b24c. [DOI] [PubMed] [Google Scholar]
- 77.Leroi A-M, Parc Y, Lehur P-A, Mion F, Barth X, Rullier E, Bresler L, Portier G, Michot F, Study G. Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study. Annals of Surgery. 2005;242:662–9. doi: 10.1097/01.sla.0000186281.09475.db. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Patton V, Wiklendt L, Arkwright JW, Lubowski DZ, Dinning PG. The effect of sacral nerve stimulation on distal colonic motility in patients with faecal incontinence. British Journal of Surgery. 2013;100:959–68. doi: 10.1002/bjs.9114. [DOI] [PubMed] [Google Scholar]
- 79.Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. The Lancet. 2011;377:997–1003. doi: 10.1016/S0140-6736(10)62297-0. [DOI] [PubMed] [Google Scholar]
- 80.Norton C. Treating faecal incontinence with bulking-agent injections. The Lancet. 2011;377:971–972. doi: 10.1016/S0140-6736(11)60173-6. [DOI] [PubMed] [Google Scholar]
- 81.Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database of Systematic Reviews. 2013 doi: 10.1002/14651858.CD007959.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Dehli T, Stordahl A, Vatten LJ, Romundstad PR, Mevik K, Sahlin Y, Lindsetmo RO, Vonen B. Sphincter training or anal injections of dextranomer for treatment of anal incontinence: a randomized trial. Scandinavian Journal of Gastroenterology. 2013;48:302–10. doi: 10.3109/00365521.2012.758770. [DOI] [PubMed] [Google Scholar]